A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer

NCT04562298 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
15
Enrollment
OTHER
Sponsor class

Stopped Both the sponsors and collaborator are considering terminating the study.

Conditions

Interventions

Sponsor

Shanghai East Hospital

Collaborators